4 results
This study is being performed to evaluate the cognitive and psychomotor effects of the new compound LY2624803 after bedtime dosing.
Primary Objective:The primary objective of this study is to determine whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive…
To assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer*s disease-causing mutation by determining if treatment with the study drug slows the rate of progression…
In the Phase 2 clinical study, the efficacy of the vaccine in non-responders and the safety of the vaccine will be studied.